Company Overview

Manhattan Scientifics, Inc. (OTCQB: MHTX) is a technology commercialization and intellectual property development company focused on advanced materials, nanotechnology, and healthcare-related innovations. The company operates primarily as an incubator and strategic investor in emerging technologies developed through university research partnerships and affiliated ventures. Its business model centers on identifying commercially viable scientific breakthroughs, supporting product development, securing intellectual property rights, and pursuing licensing, partnerships, or equity value creation opportunities.

Historically, Manhattan Scientifics evolved from a broader technology holding and venture commercialization platform into a more focused organization emphasizing healthcare diagnostics and advanced engineering technologies. Public disclosures and market filings indicate that the company has concentrated significant attention on two principal technology platforms: Imagion Biosystems, Inc., which develops magnetic nanoparticle imaging technologies for cancer diagnostics, and Senior Scientific LLC, which has pursued applications involving nanomaterials and hydrogen-related technologies. The company’s positioning has been tied to early-stage scientific innovation commercialization rather than large-scale manufacturing or diversified industrial operations.

Business Operations

Manhattan Scientifics generates value primarily through equity ownership, intellectual property interests, licensing arrangements, and strategic commercialization activities tied to its affiliated technology companies. The company has historically reported operations linked to investments in medical imaging technologies, nanotechnology applications, and advanced material sciences. Its business structure differs from conventional operating companies because a substantial portion of its activities involves incubation, research collaboration, portfolio management, and technology development rather than direct end-product sales.

Operations have included activities in both the United States and international markets through affiliated entities and investment relationships. Imagion Biosystems, Inc., an Australia-listed company in which Manhattan Scientifics has held a significant ownership interest, represents one of the company’s most visible strategic holdings. The company has also been associated with Senior Scientific LLC, which has explored nanocluster and hydrogen-related technologies. Publicly available filings indicate that Manhattan Scientifics relies heavily on partnerships with research institutions, scientists, and commercialization partners to advance its technologies toward regulatory, clinical, or industrial adoption.

Strategic Position & Investments

The company’s strategic direction has focused on advancing high-potential scientific technologies from research environments into commercially scalable applications. Management has emphasized healthcare diagnostics, nanotechnology-enabled systems, and advanced materials as core long-term opportunity areas. Manhattan Scientifics has historically concentrated investment resources on technologies that could address unmet needs in cancer detection, imaging precision, and energy-related materials applications.

A major strategic investment has been the company’s stake in Imagion Biosystems, Inc., which develops magnetic relaxometry imaging technology intended to improve cancer detection using targeted magnetic nanoparticles. Manhattan Scientifics has also maintained involvement with Senior Scientific LLC, whose research initiatives have included hydrogen production concepts and nanomaterial engineering. Available public information suggests that the company’s investment approach is selective and highly concentrated, with performance materially influenced by the progress of a limited number of affiliated ventures. Some operational and commercialization timelines associated with these technologies remain subject to regulatory, financing, and technical development milestones.

Geographic Footprint

Manhattan Scientifics is headquartered in the United States, with corporate operations historically associated with New Mexico. Its commercial and investment activities have extended internationally through portfolio relationships, most notably via Australia through its involvement with Imagion Biosystems, Inc. The company’s operational footprint is relatively limited compared with multinational industrial firms, reflecting its role as a technology commercialization and investment organization rather than a large-scale operator.

The company’s influence has primarily been concentrated in research-intensive markets involving university innovation ecosystems, healthcare technology development, and advanced scientific engineering. Public filings and investor materials indicate that its international exposure has largely occurred through investment holdings, licensing activities, and scientific collaborations rather than broad physical infrastructure or manufacturing networks across multiple continents.

Leadership & Governance

Manhattan Scientifics’ leadership has historically emphasized scientific commercialization, capital discipline, and long-term intellectual property development. Governance and strategic oversight have focused on evaluating emerging technologies with potential for commercialization in healthcare diagnostics, nanotechnology, and advanced materials. Public company disclosures indicate that management strategy has centered on building shareholder value through selective incubation and investment in disruptive technologies.

Key executives and leadership figures identified in public filings and corporate disclosures include:

• Dennis Alexander – Chief Executive Officer
• Doug Schwartz – Chief Financial Officer
• Leonard W. Osborn – Chairman of the Board

Data regarding broader executive leadership structures, operational management depth, and long-term succession planning is limited in publicly available sources. Some historical leadership information across filings and market databases varies by reporting period.